Promedior avoids redundancy

Promedior's PRM-151 prevents fibrosis by blocking monocyte activation

Promedior Inc. is hoping that blocking monocyte activation will be a better approach for preventing fibrosis than targeting stimulatory cytokines or growth factors, because the cells targeted by its PRM-151 are far enough upstream that they cannot be circumvented by the redundant mechanisms that contribute to fibrosis.

The company was set to report this week that it has started a Phase IIa trial of PRM-151 designed to

Read the full 666 word article

How to gain access

Continue reading with a
two-week free trial.